Archive · 15 Jun 2025
Diabetes Treatment Access Faces Barriers in Lower-Income Countries
New medicines help people with diabetes, but they're too expensive for many people in poorer countries.
Drug companies use patents to keep prices high, even when cheaper versions could be made.
A global health organization is trying to make the drugs more accessible.
A court case in India will decide if cheaper, generic versions can be produced, which could lower prices.
The court's decision will affect whether many people worldwide can afford the treatments they need.
New diabetes treatments are effective but expensive, limiting access in low- and middle-income countries.
Pharmaceutical companies use patents to extend monopolies, keeping prices high.
The World Health Organization is considering adding diabetes drugs to its essential medicines list.
A court case in India will determine if generic versions of a key diabetes drug can be produced.
The outcome of the legal battle could greatly impact the affordability of diabetes treatment globally.
- Who
- Pharmaceutical companies like Novo Nordisk and Dr. Reddy's Laboratories, patients with diabetes, the World Health Organization, and the Delhi High Court.
- What
- A dispute over access to affordable diabetes treatment.
- When
- The article was published on June 15, 2025, and discusses events happening in 2025.
- Where
- Primarily in India and low- and middle-income countries (LMICs).
- Why
- To determine whether affordable diabetes treatments will be accessible to people in low- and middle-income countries.
Patients & Generic Drug Manufacturers
Pharmaceutical Companies
Patent Protection vs. Public Health
Patients & Generic Drug Manufacturers
Want affordable access to life-saving medication, allowing them to benefit from new treatments.
Pharmaceutical Companies
Pharmaceutical companies seek to protect their intellectual property and maximize profits, often extending monopolies via patenting strategies.
- Drug Example
- Semaglutide (Ozempic)
- Another Drug Example
- Tirzepatide (Mounjaro)
- Drug Company 1
- Novo Nordisk
- Drug Company 2
- Eli Lilly
- Generic Drug Company
- Dr. Reddy’s Laboratories (DRL)
- Compound Patent Expiry (Semaglutide)
- 2026
- Compound Patent Expiry (Tirzepatide)
- 2036
- Potential Generic Price (Semaglutide)
- Under $6 a month